Combination meningitidis B/C vaccines
AssigneesNovartis AG, Statens Institutt for Folkehelse
InventorsDan M. Granoff, Howard Raff, Ingeborg S. Aaberge, Bjorn Haneberg, Johan Holst
Life of this patent
Estimating the term…
Abstract
Combination vaccines for treating or preventing Neisseria meningitidis infection are described. The vaccines include Neisseria meningitidis serogroup B proteoliposomic vesicles and Neissera meningitidis serogroup C conjugated oligosaccharides.
Claims11
An immunogenic composition comprising a first antigen, a second antigen and an adjuvant, wherein:
- (a) the first antigen is a capsular oligosaccharide from serogroup C N. meningitidis (NmC) conjugated to CRM197;
- (b) the second antigen is proteoliposomic vesicles from serogroup B of N. meningitidis (NmB);
- and (c) the adjuvant is MF59.
An immunogenic composition comprising an immunologically effective amount of a first antigen and an immunologically effective amount of a second antigen, wherein:
- (a) the first antigen is a capsular oligosaccharide from serogroup C N. meningitidis (NmC), conjugated to CRM197, and contains from 12 to 22 repeating units from the NmC capsular polysaccharide and (b) the second antigen is proteoliposomic vesicles from strain 44/76 (B15:P1.7, 16:L3,7,9) of serogroup B N. meningitidis (NmB), wherein said proteoliposomic vesicles are produced by a deoxycholate extraction process.
An immunogenic composition comprising a first antigen, a second antigen and an adjuvant, wherein:
- (a) the first antigen is a capsular oligosaccharide from serogroup C N. meningitidis containing 12 to about 22 repeating units from N. meningitidis serogroup C capsular polysaccharide conjugated to a carrier, and (b) the second antigen is proteoliposomic vesicles from serogroup B of N. meningitidis (NmB).
Dependencies are inferred from the claim text.